Despite its potential as a tumor progression biomarker (6–8) and the growing need for non-invasive methods to monitor brain tumor recurrence, such as liquid biopsy (9), only a few clinical trials have assessed MMP-9 in this context. The gene discussed is MMP9; the disease is neoplasm.